Clinical trials: Corneal Disease
Corneal Disease, Fuch's Dystrophy
Cornea Donor Study
The Cornea Donor Study (CDS) was designed as a prospective cohort study with the following objectives: To determine whether the graft-failure rate over a 5-year follow-up period following corneal transplantation is the same when…
- Conditions
- Corneal Disease, Fuch's Dystrophy, Pseudophakic Corneal Edema
- Trial name
- CDS (NCT00006411)
- Testing
- corneas assigned by donor age group
- Where
- United States
- Volunteers
- 1,090 people
- Sponsor
- National Eye Institute (NEI)
Corneal Endothelial Cell Loss
Comparative Study of Specular Microscopes for Measurements of Cell Density, Coefficient of Variation and Hexagonality
The primary objective of this clinical study is to collect clinical data to support an FDA 510(k) submission for the Nidek CEM-530 Center point method and Corner point method.
- Trial name
- NCT02276638
- Testing
- Specular Microscope Nidek CEM-530, Specular Microscope Konan CELLCHEK XL
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Nidek Co. LTD.
Keratoconjunctivitis Sicca
Trial of CF101 to Treat Patients With Dry Eye Disease
Eligible patients with dry eye will be treated with CF101 or placebo twice daily for 24 weeks. Disease activity will be assessed using evaluations of ocular surface integrity, tear production, and patient symptoms.
- Trial name
- NCT01235234
- Testing
- CF101
- Where
- Israel
- Volunteers
- 236 people
- Sponsor
- Can-Fite BioPharma
Corneal Edema, Corneal Endothelial Dysfunction
A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1)
The goal of this clinical trial is to compare different doses of AURN001 in patients with corneal edema secondary to corneal endothelial dysfunction.
- Trial name
- CLARA (NCT06041256)
- Testing
- AURN001, Corneal Endothelial Cells, Y27632
- Where
- 20 sites in United States, Canada
- Volunteers
- 97 people
- Sponsor
- Aurion Biotech
Trachoma
A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial
Infection with C. Trachomatis has decreased substantially in trachoma endemic areas following repeated annual mass drug administration (MDA) with azithromycin, although not as rapidly as anticipated.
- Trial name
- ASANTE (NCT01767506)
- Testing
- Surveillance and treatment with azithromycin of newcomer and traveler families, Usual care
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Trachoma
Modified Instrumentation for Surgery to Correct Trichiasis
Trachoma, an ocular infection caused by C. trachomatis, is the second leading infectious cause of blindness worldwide. Years of repeated infection with C.
- Trial name
- NCT00886015
- Testing
- TT Clamp, Standard BLTR Technique
- Where
- United States
- Volunteers
- 1,927 people
- Sponsor
- Johns Hopkins University
FSGS, MCD
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
Adalimumab, a treatment which blocks tumor necrosis factor (TNF), was tested to see if it changed levels of urine biomarker levels, tissue inhibitor of metalloprotease-1 (TIMP1), and monocyte chemoattractant protein-1 (MCP1).
- Conditions
- FSGS, MCD, Focal Segmental Glomerulosclerosis, Minimal Change Disease
- Trial name
- NCT04009668
- Testing
- adalimumab
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan
Chronic Graft-versus-host Disease
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
To assess the efficacy of R348 Ophthalmic Solutions administered for 12 weeks to subjects evaluated by objective and subjective measures.
- Trial name
- DROPS-2 (NCT02040623)
- Testing
- R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Rigel Pharmaceuticals
Cataract
Clinical Study to Evaluate the RxSight Light Adjustable Lens With the Light Delivery Device in Subjects With Preoperative Corneal Astigmatism
For patients undergoing cataract surgery, the purpose of this study is to evaluate a patient's far vision without glasses and quality of vision after implantation and UV treatment of the RxSight Light Adjustable Lens…
- Trial name
- NCT03771352
- Testing
- RxSight RxLAL
- Where
- 3 sites in Germany, United Kingdom
- Volunteers
- 55 people
- Sponsor
- RxSight, Inc.
Fuchs' Dystrophy, Corneal Edema
Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty
Graft rejection has traditionally been one of the leading causes of cornea transplant failure. To help prevent rejection, corticosteroid eye drops are used for an extended period after transplant surgery.
- Trial name
- NCT01853696
- Testing
- loteprednol etabonate, prednisolone acetate 1%
- Where
- United States
- Volunteers
- 167 people
- Sponsor
- Cornea Research Foundation of America
Diabetes
A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds
As a consequence of damage to multiple organ systems throughout the course of their disease, diabetic patients suffer a number of chronic complications giving rise to increased morbidity, mortality, and health care costs specific…
- Trial name
- NCT00598871
- Testing
- Thymosin Beta 4 (Tβ4)
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- ReGenTree, LLC
Corneal Neovascularization
Topical Avastin for Treatment of Corneal Neovascularization
The purpose of this study is to determine the effectiveness and safety of Topical Bevacizumab (Avastin) for treatment of corneal neovascularization.
- Trial name
- NCT00559936
- Testing
- Topical Avastin 1%
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Keratoconjunctivitis Sicca, Dry Eye Disease
Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
This is a Phase 2/3 study to evaluate the safety and efficacy of 2 different dose concentrations of OTX-101 dosed twice a day in both eyes for 84 days compared to placebo (vehicle) in patients with keratoconjunctivitis sicca (dry…
- Trial name
- NCT02254265
- Testing
- OTX-101 0.05%, OTX-101 0.09%, Vehicle
- Where
- United States
- Volunteers
- 455 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Refractive Error, Dry Eye
Determination of Cell Population in Solution-Induced Corneal Staining (SICS) and Symptomatic Versus Asymptomatic Lens Wearers
The purpose of the study is to investigate the corneal epithelial cell response associated with lens wear that results in solution-induced corneal staining (Phase1) and to determine the cell appearance in symptomatic and…
- Trial name
- ABBOTSFORD (NCT01629706)
- Testing
- Balafilcon A contact lens, Habitual contact lenses, Renu multi-purpose solution
- Volunteers
- 92 people
- Sponsor
- CIBA VISION
Dry Eye Syndrome, Keratoconjunctivitis Sicca
Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome
A Multi-Center, Phase 2/3, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Voclosporin Ophthalmic Solution (0.05%, 0.10%, 0.20%) Compared to Vehicle in Subjects…
- Trial name
- AUDREY (NCT04147650)
- Testing
- 0.05% Voclosporin Ophthalmic Solution (VOS), 0.10% VOS, 0.20% VOS
- Where
- 9 sites in United States
- Volunteers
- 508 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Corneal Endothelial Cell Loss, Ocular Pain
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
This study assesses the efficacy and safety of two concentrations of omaveloxolone (RTA 408) ophthalmic suspension for the prevention of corneal endothelial cell loss following cataract surgery.
- Conditions
- Corneal Endothelial Cell Loss, Ocular Pain, Ocular Inflammation, Cataract Surgery
- Trial name
- NCT02128113
- Testing
- Vehicle Ophthalmic Solution, Omaveloxolone Ophthalmic Suspension 0.5%, Omaveloxolone Ophthalmic Suspension 1%
- Where
- 15 sites in United States
- Volunteers
- 307 people
- Sponsor
- Biogen
Corneal Edema
A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy
Two different dosing regimens (QD and BID) of netarsudil will be studied to evaluate their efficacy in reducing or resolving corneal edema in subjects with FCD.
- Trial name
- Fuchs (NCT04498169)
- Testing
- Netarsudil Ophthalmic
- Where
- 12 sites in United States
- Volunteers
- 40 people
- Sponsor
- Aerie Pharmaceuticals
Aphakia, Cataract
Clinical Study to Evaluate the Safety and Effectiveness of the RxSight Light Adjustable Lens (LAL) in Subjects With Prior Corneal Refractive Surgery
The primary objective of this study is to evaluate, for the visual correction of aphakia, the safety and effectiveness of the RxSight Light Adjustable Lens (LAL) and Light Delivery Device (LDD) to reduce postoperative refractive…
- Trial name
- NCT03660865
- Testing
- Light Adjustable lens (LAL) and Light Delivery Device (LDD), Control IOL
- Where
- 6 sites in United States
- Volunteers
- 105 people
- Sponsor
- RxSight, Inc.
Trachoma
Azithromycin Reduction to Reach Elimination of Trachoma
The investigators propose a randomized controlled trial of discontinuation versus continuation of annual mass azithromycin distribution in hypoendemic communities of Maradi, Niger.
- Trial name
- ARRET (NCT04185402)
- Testing
- Azithromycin
- Where
- Niger
- Volunteers
- 3,931 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Persistent Corneal Epithelial Defects
Efficacy and Safety Study of Nexagon for Persistent Corneal Epithelial Defects
The purpose of this study is to evaluate the efficacy and safety of Nexagon® in subjects with persistent corneal epithelial defects (PED) resulting from corneal epithelial debridement during diabetic vitrectomy surgery, HSV…
- Trial name
- NTX-PED-001 (NCT01165450)
- Testing
- Nexagon, Vehicle only
- Volunteers
- 2 people
- Sponsor
- University of California, San Francisco